American Red Cross: Celebrate Black History Month by Participating in a ‘Sleeves Up’ Campaign

February is Black History Month  – a time to honor the significant achievements of Black Americans while making an impact today. This year’s theme focuses on the importance of Black health and wellness. The American Red Cross is honoring the legacy of Dr. Charles Drew, an African American surgeon, and researcher who pioneered new methods for collecting, preserving, and distributing blood, as well as storing blood plasma for transfusion. We work to celebrate his advancements by putting a challenge out to the entire Georgia Region.

“Dr. Drew’s work with the Red Cross Blood Program helped save the lives of hundreds of thousands of people,” said Dee Dixon, CEO of Georgia’s Red Cross. “With blood transfusions remaining one of the most critical treatments for patients with chronic illnesses such as sickle cell, I invite Georgians everywhere to continue Dr. Drew’s lifesaving legacy by rolling up a sleeve to give blood during Black History Month.”

No bloodmobile or space is needed to answer this challenge, making it especially convenient for students and organizations to get involved. Simply create your campaign online, and send an invitation to your friends and family members anywhere in Georgia to join you in donating blood and saving lives.

Participants can visit  www.redcrossblood.org  to enter their zip code and find/book a convenient blood donation appointment in February or upcoming months.

Once participants are ready to roll up a sleeve, we want to see it! We invite all campaign blood donors to snap a picture and share it on social media using the hashtags:  #TeamUp4SickleCellGA & #BlackBloodDonorsNeeded

Calendar opportunities for launching an inspiring Sleeves Up Campaign during Black History Month / American Heart Month include:

  • African Heritage and Health Week – Feb. 1-7
  • Rosa Parks Day – Feb. 5
  • National Black HIV/AIDS Awareness Day – Feb. 7
  • National Donor Day – Feb. 14
  • Frederick Douglass Day – Feb. 14
  • National Black Girl Magic Day – Feb. 15
  • World Day of Social Justice – Feb. 20
  • Black Lives Matter Day – Feb. 26
  • Rare Disease Day – Feb. 28

Blood donations from everyone remain essential to the health of communities. However, African American donors play a critical role in meeting the need for blood – especially for those with sickle cell disease who often rely on closely matched blood products for regular transfusions. Individuals of all blood types are urged to make an appointment now to give blood or platelets in the weeks ahead by using the  Red Cross Blood DonorApp , visiting  RedCrossBlood.org , or calling  1 800-RED CROSS (1-800-733-2767) .

 As an extra thank-you during Black History Month, those who come to give in February will receive a $10  Amazon.com  Gift Card via email,  thanks to Amazon.

The Red Cross is currently providing free sickle cell trait screening on all donations from self-identified African American donors in addition to a free mini health screening with insights on pulse, blood pressure and hemoglobin levels.

About the American Red Cross:

The American Red Cross shelters, feeds, and provides emotional support to victims of disasters; supplies about 40 percent of the nation’s blood; teaches skills that save lives; provides international humanitarian aid; and supports military members and their families. The Red Cross is a not-for-profit organization that depends on volunteers and the generosity of the American public to perform its mission. For more information, please visit  redcross.org  or  cruzrojaamericana.org .

August 21, 2026
Genetic Engineering & Biotechnology News (GEN) has named Georgia #4 among its “Next 5 States” for emerging U.S. biopharma clusters . The article highlights UCB’s planned $2 billion investment at in Gwinnett County, Micron Biomedical’s new Alpharetta facility, Manus Bio’s expansion in Augusta, Science Square, Emory University, the CDC — and Georgia Life Sciences’ 10-year Life Sciences Roadmap . This recognition is exciting. But even more importantly, it validates the work happening across our entire ecosystem — and perfect momentum as we head into the 2026 Georgia Life Sciences Summit next week. Read more by visiting: Next 10 U.S. Biopharma Clusters
August 17, 2026
Biotechnology Innovation Organization (BIO) Senior Vice President of Science & Regulatory Affairs Annetta Beauregard issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VIII commitment letter: “For more than 30 years, PDUFA has helped deliver hundreds of new medicines to American patients. As a lead industry negotiator for the PDUFA VIII agreement, BIO supports the PDUFA VIII commitment letter and its strengthening of regulatory review, advancing innovation, and helping deliver safe and effective treatments to patients. “Specifically, the PDUFA VIII agreement includes important commitments that bolster the FDA’s core review activities, ensure accountability for predictable performance, improve financial sustainability and improve communication, transparency and efficiency. “Timely, bipartisan reauthorization of PDUFA is vital for protecting the health of Americans, strengthening U.S. competitiveness, and maintaining America’s global leadership in medical innovation. BIO is committed to working with Congress to ensure reauthorization by September 30, 2027.” The FDA has announced plans to hold a hybrid public meeting at 9am on 9/16 to discuss the proposed enhancements for the reauthorization of PDUFA for fiscal years (FYs) 2028 through 2033. Learn More about PDUFA and the PDUFA VIII commitment letter HERE .
August 17, 2026
Representing Georgia’s life sciences community, GLS emphasized the importance of advancing policies that improve affordability and patient access while preserving the environment necessary for continued biomedical innovation. In its comments, GLS urged CMS to maintain a framework grounded in FDA regulatory determinations and raised concerns about how certain proposed policies could affect post-approval research and development, investment in new indications, and patient access to innovative therapies. GLS also encouraged CMS to consider the broader implications for healthcare delivery, including the potential impact on patients and providers in rural and underserved communities. As federal drug pricing policy continues to evolve, Georgia Life Sciences will continue to advocate for approaches that balance affordability, access, and innovation while ensuring Georgia’s life sciences community has a voice in the policymaking process. Read Georgia Life Sciences’ full comments to CMS ( click here ).
MORE POSTS